279 related articles for article (PubMed ID: 22782962)
1. Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Ikeda M; Fujita T; Mii S; Tanabe K; Tabata K; Matsumoto K; Satoh T; Iwamura M
Jpn J Clin Oncol; 2012 Sep; 42(9):820-4. PubMed ID: 22782962
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Bilaç C; Müezzinoğlu T; Ermertcan AT; Kayhan TC; Temeltaş G; Oztürkcan S; Temiz P
Cutan Ocul Toxicol; 2009; 28(2):90-2. PubMed ID: 19514932
[TBL] [Abstract][Full Text] [Related]
3. Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Akaza H; Tsukamoto T; Murai M; Nakajima K; Naito S
Jpn J Clin Oncol; 2007 Oct; 37(10):755-62. PubMed ID: 17951335
[TBL] [Abstract][Full Text] [Related]
4. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Ratain MJ; Eisen T; Stadler WM; Flaherty KT; Kaye SB; Rosner GL; Gore M; Desai AA; Patnaik A; Xiong HQ; Rowinsky E; Abbruzzese JL; Xia C; Simantov R; Schwartz B; O'Dwyer PJ
J Clin Oncol; 2006 Jun; 24(16):2505-12. PubMed ID: 16636341
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
6. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Yang CH; Lin WC; Chuang CK; Chang YC; Pang ST; Lin YC; Kuo TT; Hsieh JJ; Chang JW
Br J Dermatol; 2008 Mar; 158(3):592-6. PubMed ID: 18070211
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib-induced erythema multiforme: three cases.
Namba M; Tsunemi Y; Kawashima M
Eur J Dermatol; 2011; 21(6):1015-6. PubMed ID: 21926043
[No Abstract] [Full Text] [Related]
8. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
9. Erythema multiforme induced by sorafenib.
Feltes RA; Feito Rodríguez M; González-Beato MJ
Clin Exp Dermatol; 2009 Oct; 34(7):e368-9. PubMed ID: 19489856
[No Abstract] [Full Text] [Related]
10. Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Sahai S; Swick BL
Int J Dermatol; 2010 Oct; 49(10):1203-6. PubMed ID: 20883411
[TBL] [Abstract][Full Text] [Related]
11. Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Naito S; Tsukamoto T; Murai M; Fukino K; Akaza H
BJU Int; 2011 Dec; 108(11):1813-9. PubMed ID: 21481133
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib-induced erythema multiforme.
MacGregor JL; Silvers DN; Grossman ME; Sherman WH
J Am Acad Dermatol; 2007 Mar; 56(3):527-8. PubMed ID: 17241689
[No Abstract] [Full Text] [Related]
14. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Stadler WM; Figlin RA; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; George JR; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Bukowski RM;
Cancer; 2010 Mar; 116(5):1272-80. PubMed ID: 20082451
[TBL] [Abstract][Full Text] [Related]
15. Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation.
Miyake H; Kurahashi T; Yamanaka K; Kondo Y; Muramaki M; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2010; 28(5):515-9. PubMed ID: 19914105
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
17. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Kennoki T; Kondo T; Kimata N; Murakami J; Ishimori I; Nakazawa H; Hashimoto Y; Kobayashi H; Iizuka J; Takagi T; Yoshida K; Tanabe K
Jpn J Clin Oncol; 2011 May; 41(5):647-55. PubMed ID: 21367805
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Kodaira M; Takahashi S; Takeuchi K; Yuasa T; Saotome T; Yonese J; Fukui I; Hatake K
Ann Oncol; 2010 Jul; 21(7):1563-1565. PubMed ID: 20573851
[No Abstract] [Full Text] [Related]
19. Sorafenib-induced palmoplantar hyperkeratosis.
Lountzis NI; Maroon MS
J Drugs Dermatol; 2008 Jun; 7(6):588-9. PubMed ID: 18561593
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Bukowski RM; Stadler WM; McDermott DF; Dutcher JP; Knox JJ; Miller WH; Hainsworth JD; Henderson CA; Hajdenberg J; Kindwall-Keller TL; Ernstoff MS; Drabkin HA; Curti BD; Chu L; Ryan CW; Hotte SJ; Xia C; Cupit L; Figlin RA
Oncology; 2010; 78(5-6):340-7. PubMed ID: 20733337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]